The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite toxic, so an adequate supportive therapy is crucial to reduce as much as possible the side effects and maintain the dose intensity of cytotoxic agents.
Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
Turla, Antonella;Lagana, Marta;Grisanti, Salvatore;Abate, Andrea;Ferrari, Vittorio Domenico;Cremaschi, Valentina;Sigala, Sandra;Consoli, Francesca;Cosentini, Deborah;Berruti, Alfredo
2022-01-01
Abstract
The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite toxic, so an adequate supportive therapy is crucial to reduce as much as possible the side effects and maintain the dose intensity of cytotoxic agents.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
